A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design

Erstveröffentlichung
2020
Authors
Schmidt-Kraepelin, Christian
Feyerabend, Sandra
Engelke, Christina
Riesbeck, Mathias
Meisenzahl-Lechner, Eva
et al.
Wissenschaftlicher Artikel


Published in
European archives of psychiatry and clinical neuroscience ; 270 (2020), 1. - S. 83-94. - ISSN 0940-1334. - eISSN 1433-8491
Link to publication
https://dx.doi.org/10.1007/s00406-019-01063-4
Institutions
UKU. Klinik für Psychiatrie und Psychotherapie II
Bezirkskrankenhaus Günzburg
Subject headings
[Free subject headings]: Schizophrenia | Antipsychotics | Combination | Amisulpride | Olanzapine | Polypharmacy | ANTIPSYCHOTIC POLYPHARMACY | SCHIZOAFFECTIVE DISORDER | 2ND-GENERATION ANTIPSYCHOTICS | META-REGRESSION | CLOZAPINE | AUGMENTATION | RISPERIDONE | TOLERABILITY | METAANALYSIS | EFFICACY
[DDC subject group]: DDC 610 / Medicine & health
Metadata
Show full item record